Optum Health Services
Search documents
Up 40% in the Past Month, Should You Buy UnitedHealth Stock Here?
Yahoo Finance· 2025-09-10 19:12
Health insurance provider UnitedHealth (UNH) is experiencing a volatile time on Wall Street. Reasons for the volatility include the sudden announcement of its CEO’s departure. Before that, the company came under national attention when its previous CEO was murdered last year. UnitedHealth has also come under investigation by the DOJ. Amid all this, Warren Buffett decided to trust in the company’s longstanding prowess, as Berkshire Hathaway (BRK.A) (BRK.B) revealed a $1.57 billion stake in the company, sen ...
UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels
MarketBeat· 2025-04-22 12:32
Core Viewpoint - UnitedHealth Group is facing challenges with rising medical costs and utilization, leading to a lowered earnings guidance for 2025, but its diversified business model and vertical integration provide resilience in a tough market [1][9][10]. Financial Performance - For Q1 2025, UnitedHealth reported earnings per share (EPS) of $7.20, missing consensus estimates by $0.09, while revenues grew 9.8% year-over-year to $109.58 billion, falling short of the $111.58 billion consensus [5]. - The Optum subsidiary generated 42% of the company's operating profits, with Q1 revenue of $63.9 billion, up 4.4% year-over-year [6]. - The medical care ratio (MCR) was reported at 84.8%, slightly up from 84.3% in Q1 2024, indicating a strong cost containment strategy [7]. Market Position and Sentiment - Despite negative sentiment towards health insurers due to rising costs, UnitedHealth is viewed as the best option in a challenging environment due to its integrated healthcare model [4]. - The stock has seen fluctuations, recovering from a low of $425.39 to a high of $606.36 in April 2025, but has recently faced a downturn due to lowered earnings guidance [2][16]. Future Outlook - The company has adjusted its full-year 2025 EPS guidance to a range of $26.00 to $26.50, significantly lower than the previous consensus of $29.72, primarily due to increased medical care activity [9]. - Management remains optimistic about growth, particularly in OptumRx, and anticipates an increase in Medicare Advantage (MA) plan membership by 800,000 in 2025 [10][13]. - The Center for Medicare and Medicaid Services (CMS) announced a 5.06% increase in MA plan reimbursements for 2026, which could serve as a positive catalyst for the company [12].